Literature DB >> 16138352

Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.

Rossella R Cacciola1, Antonio Cipolla, Ernesto Di Francesco, Rosario Giustolisi, Emma Cacciola.   

Abstract

We prospectively evaluated the effect of anagrelide (ANA) on platelets, PF4, F1+2, PAP, PAI-1, and TFPI and erythromelalgia in patients with essential thrombocythemia (ET) receiving anti-aggregants both pre- and post-ANA. At first, we observed a successful reduction of platelets, which was associated with normalization of platelet coagulant and endothelial function and disappearance of erythromelalgia. Secondly, we found a correlation between PF4 and TFPI and between TFPI and thrombosis, suggesting that erythromelalgia may be caused by platelet-mediated endothelial activation. These data may indicate that ANA may be efficacy in the treatment of symptomatic patients with ET. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16138352     DOI： 10.1002/ajh.20399

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  4 in total

Review 1.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.

Authors:  Shinichiro Okamoto; Yoshitaka Miyakawa; Jonathan Smith; Ian Hodgson; Brihad Abhyankar; Steven Troy; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2013-02-03       Impact factor: 2.490

Review 3.  Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.

Authors:  Mohsen Maleknia; Saeid Shahrabi; Majid Ghanavat; Tina Vosoughi; Najmaldin Saki
Journal:  Mol Biol Rep       Date:  2020-05-30       Impact factor: 2.316

4.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.